Lonafarnib: all 27 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaEnrolling by invitationNCT02579044Phase 1/2
- Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda InterferonCompletedNCT03600714Phase 2Results posted
- Titrating-Dose of Lonafarnib in Combination With RitonavirCompletedNCT02527707Phase 2Results posted
- Treatment of Chronic Delta Hepatitis With Lonafarnib and RitonavirCompletedNCT02511431Phase 2Results posted
- Lonafarnib for Chronic Hepatitis DCompletedNCT01495585Phase 2Results posted
- A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaCompletedNCT00879034Phase 2Results posted
- Lonafarnib in Metastatic Breast CancerTerminatedNCT00773474Phase 2Results posted
- Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaCompletedNCT00425607Phase 2Results posted
- Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus InfectionCompletedNCT05229991Phase 3
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCompletedNCT03719313Phase 3
- PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasCompletedNCT00612651Phase 1
- A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)TerminatedNCT00539968Phase 1/2
- Interaction of Docetaxel and Lonafarnib in Patients With Advanced CancerTerminatedNCT00288444Phase 1
- Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian CancerCompletedNCT00281515Phase 2
- Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)TerminatedNCT00109538Phase 3
- Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideActive, not recruitingNCT00102648Phase 1
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedNCT00102635Phase 1
- Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial GliomasStatus unknownNCT00083096Phase 1
- Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)CompletedNCT00081510Phase 2
- Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast CancerCompletedNCT00068757Phase 1
- Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)TerminatedNCT00050336Phase 3
- Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
- Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedNCT00038597Phase 2
- A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell CancerCompletedNCT00038584Phase 1
- Temozolomide and SCH66336 for Recurrent Glioblastoma MultiformeCompletedNCT00038493Phase 2
- SCH 66336 in Treating Children With Recurrent or Progressive Brain TumorsCompletedNCT00015899Phase 1
- SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the LiverWithdrawnNCT00005030Phase 1